Plexxikon Inc. v. Novartis Pharmaceuticals Corporation

Background

This patent-infringement case concerns Plexxikon’s patents for kinase inhibitors. Plexxikon accused Novartis of infringing those patents through Tafinlar, a melanoma drug that Novartis acquired from GlaxoSmithKline in 2015. Tafinlar inhibits B-Raf, a type of kinase, and was approved both by itself and in combination with Mekinist, an MEK inhibitor. Plexxikon’s product, Zelboraf, was also approved for combination use with an MEK inhibitor, Cotellic.

The Tafinlar-Mekinist combination received Food and Drug Administration approval in January 2014, about two years before the Zelboraf-Cotellic combination received approval in November 2015. Plexxikon’s expert, Ted Sweeney, described a “first-mover advantage”—the tendency of a new pharmaceutical product to retain market share because it reached the market first rather than because it was inherently better than later competitors. Sweeney concluded that Novartis benefited from this advantage and that it largely explained Tafinlar-Mekinist’s higher market share compared with Zelboraf-Cotellic.

Novartis’s Motion

Novartis moved to exclude Sweeney’s testimony under Federal Rule of Evidence 702. That rule permits qualified experts to testify when their specialized knowledge will help the factfinder, their testimony rests on sufficient facts or data, their principles and methods are reliable, and they reliably applied those principles and methods to the case. The court also considered the reliability and relevance requirements described in Daubert v. Merrell Dow Pharmaceuticals, Inc.

Novartis argued that Sweeney was not qualified because he lacked an economics degree and had never previously testified as an expert. It also argued that his opinions lacked a sufficient factual basis because he did not rely on GlaxoSmithKline documents or testimony when discussing Tafinlar’s pricing decisions. Finally, Novartis argued that Sweeney’s methodology was unreliable because he did not quantify the size or duration of the alleged first-mover advantage and did not consider certain facts, including marketing and prescribing practices.

Court’s Analysis

The court held that Rule 702 takes a broad approach to expert qualifications. Sweeney’s report described approximately 20 years of consulting work in the biopharmaceutical industry, including analysis of pricing, demand, and access for biopharmaceutical products. He was the President and Managing Partner of Jupiter Life Science Consulting. The court found that this experience supported his qualification to testify about pharmaceutical market dynamics and the first-mover advantage, even though he did not have an economics degree and had not previously testified as an expert.

The court also found an adequate factual basis. Sweeney discussed price and sales data for the four drug products and explained his views about pricing in the oncology market. The court stated that relying on market dynamics and industry experience rather than GlaxoSmithKline’s internal documents or representations did not make his opinions baseless.

On methodology, the court explained that Rule 702 and Daubert do not require every expert analysis to be quantitative. The court found that a qualitative analysis based on specialized knowledge and experience could be reliable. It further concluded that the additional facts Novartis identified did not make Sweeney’s opinion so unreliable that exclusion was required. The court emphasized that Novartis could challenge Sweeney through cross-examination and contrary evidence, and that the jury—not the court—would decide how persuasive his testimony was.

Disposition

The court DENIED Novartis’s motion to exclude Ted Sweeney’s expert testimony. The order addressed the admissibility of evidence for trial; it did not decide the underlying patent-infringement dispute.